UC Davis Comparative Oncology Training Program

加州大学戴维斯分校比较肿瘤学培训计划

• 批准号: 10248520
• 负责人: Robert J. Canter
• 金额: $ 43.4万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10248520
• 关键词: Oncology; Training Programs; comparative

Project Summary/Abstract Preclinical animal models have been the foundation for the development of novel cancer therapies. Historically, this foundation has relied on mouse models. While mouse models are fundamentally important, the models are insufficient and need to be complemented. Companion animals are an important combination of outbred animals that have spontaneous cancer development with an intact immune system and have environmental and epigenetic exposures as humans. Tackling complex cancer research problems should include investigators with broad experience across animal and human species presenting a unique opportunity for DVMs and MDs to have a crucial role in basic to translational research. Veterinarians can strengthen comparative approaches essential to multidisciplinary research accelerating innovative treatments for animals and humans. Medical doctors bring a patient-centered approach linking biology with clinical therapy. Unfortunately, recruiting and retaining biomedical scientists with comparative oncology expertise, especially DVM or MD clinician-scientists, continues to be a challenging issue facing the broader research community. The Comparative Oncology Training Program (T32) will provide an outstanding environment to train predoctoral (DVM/PhD) students and post-DVM or post-MD fellows who are interested in cancer research. To accomplish this goal, Drs. Chen, Kent, and Canter (MPIs) organized a diverse team of twenty-seven UC Davis faculty mentors from the School of Veterinary Medicine, School of Medicine, College of Biological Science, College of Agricultural and Environmental Sciences, and College of Engineering. The faculty mentors are accomplished biomedical investigators with NCI or cancer-related funding. The proposed program will leverage the NCI-designated UC Davis Comprehensive Cancer Center and will be fully integrated into the Center’s cancer education program. The T32 program’s objectives are to: 1) recruit and retain a diverse group of clinician-scientists that prepares them to become future leaders in academia, government service and public health, 2) expose the T32 scholars to cancer-focused career paths, and 3) train the scholars to use comparative medicine to address human cancer biology. The objectives will be accomplished by providing up to 3-year funding support for DVM/PhD dual-degree predoctoral students and post-DVM or post-MD postdoctoral fellows. During the training, the T32 scholars will enhance their knowledge through tailored coursework, mentored research, multidisciplinary interactions, and career development activities. By the end of the grant period, we expect to train eleven professionals encompassing two dual-degree DVM/PhD students, seven post-DVM fellows, and two post-MD fellows to become highly-qualified basic and translational comparative oncology researchers.

项目概要/摘要 临床前动物模型是开发新型癌症疗法的基础。从历史上看， 该基金会依赖于小鼠模型。虽然小鼠模型非常重要，但模型 不足，需要补充。伴侣动物是近交系的重要组合 患有自发性癌症、免疫系统完整且环境条件良好的动物 和人类的表观遗传暴露。解决复杂的癌症研究问题应包括 具有跨动物和人类物种丰富经验的研究人员提供了独特的机会 DVM 和 MD 在基础研究到转化研究中发挥着至关重要的作用。兽医可以加强 比较方法对于加速动物创新治疗的多学科研究至关重要 和人类。医生提出了一种以患者为中心的方法，将生物学与临床治疗联系起来。 不幸的是，招募和留住具有比较肿瘤学专业知识的生物医学科学家，尤其是 DVM 或 MD 临床医生科学家仍然是更​​广泛的研究界面临的一个具有挑战性的问题。 比较肿瘤学培训计划（T32）将为培训提供良好的环境 对癌症研究感兴趣的博士前 (DVM/PhD) 学生和 DVM 后或医学博士后研究员。到 实现这一目标，博士。 Chen、Kent 和 Canter (MPI) 组织了一支由 27 名加州大学戴维斯分校成员组成的多元化团队 来自兽医学院、医学院、生物科学学院的师资导师， 农业与环境科学学院和工程学院。学院导师是 获得 NCI 或癌症相关资助的杰出生物医学研究人员。拟议的计划将利用 NCI 指定的加州大学戴维斯分校综合癌症中心，并将完全融入该中心的 癌症教育计划。 T32 计划的目标是： 1) 招募并留住多元化的团队 临床医生科学家帮助他们成为学术界、政府服务和公共部门的未来领导者 健康，2）让 T32 学者了解以癌症为中心的职业道路，以及 3）培训学者使用 比较医学来解决人类癌症生物学问题。这些目标将通过提供 为 DVM/PhD 双学位博士前学生和 DVM 后或 MD 后提供 3 年资助 博士后研究员。培训期间，T32学者将通过量身定制的方式提升知识 课程作业、指导研究、多学科互动和职业发展活动。到最后 在资助期内，我们预计将培训 11 名专业人员，其中包括 2 名双学位 DVM/PhD 学生、七名 DVM 后研究员和两名 MD 后研究员成为高素质的基础和转化人员 比较肿瘤学研究人员。